GSK finalises manufacturing facility agreement

Healthcare company GlaxoSmithKline (GSK) has finalised a previously reported agreement-in-principle with the US Attorney’s Office for the District of Massachusetts and the US Department of Justice (DOJ) with respect to the investigation of the company’s former manufacturing facility in Cidra, Puerto Rico.

GSK disclosed a $750m (£470m) charge to its second quarter 2010 earnings on 15 July in connection with the agreement-in-principle. No additional charge to the company’s earnings will be recorded in connection with the settlement.

The agreements to settle follow an investigation by the US government into the company’s former manufacturing site at Cidra, Puerto Rico; product liability and anti-trust litigation relating to Paxil (paroxetine), and product liability cases regarding Avandia (rosiglitazone) and other products.

GSK no longer owns the facility.